MA51315A - Compositions et méthodes permettant de traiter des troubles du snc - Google Patents

Compositions et méthodes permettant de traiter des troubles du snc

Info

Publication number
MA51315A
MA51315A MA051315A MA51315A MA51315A MA 51315 A MA51315 A MA 51315A MA 051315 A MA051315 A MA 051315A MA 51315 A MA51315 A MA 51315A MA 51315 A MA51315 A MA 51315A
Authority
MA
Morocco
Prior art keywords
compositions
methods
cns disorders
treating cns
treating
Prior art date
Application number
MA051315A
Other languages
English (en)
Inventor
Maria Jesus Blanco-Pillado
Boyd L Harrison
Daniel La
Albert Jean Robichaud
Francesco G Salituro
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MA51315A publication Critical patent/MA51315A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA051315A 2017-12-22 2018-12-21 Compositions et méthodes permettant de traiter des troubles du snc MA51315A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762610069P 2017-12-22 2017-12-22
US201762611983P 2017-12-29 2017-12-29
US201862620095P 2018-01-22 2018-01-22
US201862722781P 2018-08-24 2018-08-24
US201862734718P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
MA51315A true MA51315A (fr) 2020-10-28

Family

ID=65234663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051315A MA51315A (fr) 2017-12-22 2018-12-21 Compositions et méthodes permettant de traiter des troubles du snc

Country Status (15)

Country Link
US (1) US20210101928A1 (fr)
EP (2) EP4442695A3 (fr)
JP (3) JP7382326B2 (fr)
KR (2) KR20200104350A (fr)
CN (3) CN117946202A (fr)
AU (2) AU2018388408B2 (fr)
BR (1) BR112020012712A8 (fr)
CA (1) CA3086299A1 (fr)
DK (1) DK3728284T3 (fr)
ES (1) ES2991092T3 (fr)
IL (2) IL275562B2 (fr)
MA (1) MA51315A (fr)
MX (3) MX2020006599A (fr)
TW (2) TWI835765B (fr)
WO (1) WO2019126741A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000008T1 (it) 2012-01-23 2020-03-13 Sage Therapeutics Inc Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
CN113527400B (zh) 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
WO2015195962A1 (fr) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Stéroïdes neuroactifs, leurs compositions et utilisations
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ME03749B (fr) 2014-11-27 2021-04-20 Sage Therapeutics Inc Compositions et procédés pour traiter des troubles du snc
WO2018013613A1 (fr) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
CN115974956A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
DK3864022T3 (da) 2018-10-12 2023-12-18 Sage Therapeutics Inc Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser
CN113301901B (zh) * 2019-01-14 2022-09-09 北京轩义医药科技有限公司 四唑啉酮取代的类固醇及其用途
CN114206900A (zh) * 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
EP4011897A4 (fr) * 2019-08-07 2024-02-21 Shanghai Hansoh Biomedical Co., Ltd. Sel et forme cristalline d'un régulateur de dérivé de stéroïde
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
EP4172171A1 (fr) 2020-06-24 2023-05-03 Sage Therapeutics, Inc. Stéroïdes neuroactifs 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl-substitués et compositions associées
JP2023539125A (ja) * 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
IT202000021316A1 (it) * 2020-09-09 2022-03-09 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE)
CN120936616A (zh) * 2023-03-14 2025-11-11 库里亚西班牙公司 用于制备3α-羟基-3β-烷基类固醇的方法和中间体
CN119176847B (zh) * 2023-06-21 2026-05-01 北京华睿鼎信科技有限公司 一种甾类化合物及其用途、制备方法和包含该甾类化合物的药物组合物
WO2025054447A1 (fr) * 2023-09-08 2025-03-13 The Research Foundation For The State University Of New York Approche chimioprotéomique pour élucider le mécanisme d'action des 6-azastéroïdes avec une activité unique dans des mycobactéries

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3087940A (en) * 1959-02-03 1963-04-30 Advance Growth Capital Corp 19-methyl pregnene derivatives
GB1036418A (en) * 1962-07-09 1966-07-20 Syntex Corp 19-alkyl-steroids and process for their production
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
DE2438020A1 (de) * 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1998005337A1 (fr) * 1996-08-01 1998-02-12 Cocensys, Inc. Utilisation de ligands de recepteurs gaba et nmda pour le traitement des cephalees de la migraine
CA3152410A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
US9512170B2 (en) * 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
CN113527400B (zh) * 2013-04-17 2024-06-28 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
AU2014308621C1 (en) * 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN106661078A (zh) * 2014-05-29 2017-05-10 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2015195962A1 (fr) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Stéroïdes neuroactifs, leurs compositions et utilisations
SMT202000414T1 (it) * 2014-10-16 2020-09-10 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
MX2021004492A (es) * 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
ME03749B (fr) * 2014-11-27 2021-04-20 Sage Therapeutics Inc Compositions et procédés pour traiter des troubles du snc
JP6875996B2 (ja) * 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
EP3280420B1 (fr) * 2015-04-10 2024-03-27 Sage Therapeutics, Inc. Compositions et méthodes permettant de traiter des troubles du snc
IL312610B2 (en) * 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them

Also Published As

Publication number Publication date
IL275562A (en) 2020-08-31
IL275562B2 (en) 2024-07-01
EP3728284B1 (fr) 2024-08-21
BR112020012712A2 (pt) 2020-11-24
US20210101928A1 (en) 2021-04-08
EP3728284A1 (fr) 2020-10-28
JP7382326B2 (ja) 2023-11-16
CA3086299A1 (fr) 2019-06-27
TW201929864A (zh) 2019-08-01
IL310454A (en) 2024-03-01
AU2024201459A1 (en) 2024-03-21
JP2021506890A (ja) 2021-02-22
JP2025072521A (ja) 2025-05-09
JP2023113862A (ja) 2023-08-16
TWI892480B (zh) 2025-08-01
BR112020012712A8 (pt) 2022-03-03
CN117946202A (zh) 2024-04-30
TW202448480A (zh) 2024-12-16
CN111770929A (zh) 2020-10-13
MX2023005098A (es) 2023-05-24
CN111770929B (zh) 2023-12-26
MX2020006599A (es) 2020-11-06
TWI835765B (zh) 2024-03-21
EP4442695A3 (fr) 2025-01-22
KR20200104350A (ko) 2020-09-03
MX2023005099A (es) 2023-05-23
AU2018388408B2 (en) 2023-12-21
IL275562B1 (en) 2024-03-01
EP4442695A2 (fr) 2024-10-09
WO2019126741A1 (fr) 2019-06-27
DK3728284T3 (da) 2024-10-28
JP7670754B2 (ja) 2025-04-30
RU2020123943A (ru) 2022-01-24
KR20250142939A (ko) 2025-09-30
CN118271387A (zh) 2024-07-02
ES2991092T3 (es) 2024-12-02
AU2018388408A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
MA51316A (fr) Compositions et méthodes permettant de traiter les troubles du snc
IL275562A (en) Preparations and methods for the treatment of central nervous system disorders
IL291533A (en) Compounds and preparations including them for the treatment of diseases of the central nervous system
EP3452028A4 (fr) Compositions et méthode pour traiter des troubles acide-base
EP3364993A4 (fr) Procédés pour traiter le syndrome d'angelman et des troubles associés
PL3250210T3 (pl) Kompozycje i sposoby leczenia zaburzeń OUN
SI3206493T1 (sl) Sestavki in metode za zdravljenje CNS motenj
EP3349760A4 (fr) Compositions et méthodes destinées à traiter les troubles neurologiques
PT3224269T (pt) Composições e métodos para tratamento de distúrbios do snc
EP3359668A4 (fr) Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
MA51074A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
EP3445368A4 (fr) Composés et procédés pour traiter des états neurologiques et cardiovasculaires
EP3328898A4 (fr) Compositions d'agoniste trkb ou trkc et méthodes de traitement de troubles otiques
EP3703706A4 (fr) Compositions et méthode pour traiter des troubles acide-base
EP3324960A4 (fr) Procédés permettant de traiter des troubles associés à l'angiogenèse et à une néovascularisation
EP3280420A4 (fr) Compositions et méthodes permettant de traiter des troubles du snc
EP3297702A4 (fr) Méthodes et compositions permettant de traiter des troubles associés au vieillissement
EP3471746A4 (fr) Méthode et composition pour traiter des troubles epileptiques
EP3454885A4 (fr) Peptides et méthodes permettant de traiter des troubles neurodégénératifs
EP3334710A4 (fr) Compositions et méthodes de traitement et de prévention de troubles neurodégénératifs
EP3661492A4 (fr) Procédés et compositions pour traiter des troubles neurologiques
EP3445369A4 (fr) Compositions et méthodes pour traiter la démence
EP3697354A4 (fr) Compositions et méthodes pour traiter des troubles oculaires
EP3796939A4 (fr) Compositions et méthodes pour traiter des troubles neurodégénératifs avec la rifaximine
EP3519050A4 (fr) Compositions et méthodes de traitement de troubles ophtalmologiques